Human CXCL13/BLC/BCA-1 Alexa Fluor® 700-conjugated Antibody
Human CXCL13/BLC/BCA-1 Alexa Fluor® 700-conjugated Antibody Summary
Accession # O43927
Complete Your Research
Complete Your Experiment
Please Note: Optimal dilutions should be determined by each laboratory for each application. General Protocols are available in the Technical Information section on our website.
Detection of CXCL13/BLC/BCA‑1 in Human Immature Dendritic Cells by Flow Cytometry. Human immature dendritic cells (CD14+PBMC cultured with 20 ng/mL rhIL-4 and 50 ng/mL rhGM-CSF for 7 days) were stained with Mouse Anti-Human CXCL13/BLC/BCA-1 Alexa Fluor® 700-conjugated Monoclonal Antibody (Catalog # IC801N, filled histogram) or isotype control antibody (Catalog # IC002P, open histo-gram). To facilitate intracellular staining, cells were fixed with Flow Cytometry Fixation Buffer (Catalog # FC004) and permeabilized with Flow Cytometry Permeabilization/ Wash Buffer I (Catalog # FC005). View our protocol for Staining Intracellular Molecules.
Preparation and Storage
- 12 months from date of receipt, 2 to 8 °C as supplied.
CXCL13, also known as B-lymphocyte chemoattractant (BLC), is a CXC chemokine that is constitutively expressed in secondary lymphoid organs. BCA-1 cDNA encodes a protein of 109 amino acid residues with a leader sequence of 22 residues. Mature human BCA-1 shares 64% amino acid sequence similarity with the mouse protein and 23-34% amino acid sequence identity with other known CXC chemokines. Recombinant or chemically synthesized BCA-1 is a potent chemoattractant for B lymphocytes but not T lymphocytes, monocytes or neutrophils. BLR1, a G protein-coupled receptor originally isolated from Burkitt’s lymphoma cells, has now been shown to be the specific receptor for BCA-1. Among cells of the hematopoietic lineages, the expression of BLR1, now designated CXCR5, is restricted to B lymphocytes and a subpopulation of T helper memory cells. Mice lacking BLR1 have been shown to lack inguinal lymph nodes. These mice were also found to have impaired development of Peyer’s patches and defective formation of primary follicles and germinal centers in the spleen as a result of the inability of B lymphocytes to migrate into B cell areas.
- Gunn, M.D. et al. (1998) Nature, 391:799.
- Legler, D.F. et al. (1998) J. Exp. Med. 187:655.
- Forster, R. et al. (1996) Cell 87:1037.
Product Specific Notices
This product is provided under an agreement between Life Technologies Corporation and R&D Systems, Inc, and the manufacture, use, sale or import of this product is subject to one or more US patents and corresponding non-US equivalents, owned by Life Technologies Corporation and its affiliates. The purchase of this product conveys to the buyer the non-transferable right to use the purchased amount of the product and components of the product only in research conducted by the buyer (whether the buyer is an academic or for-profit entity). The sale of this product is expressly conditioned on the buyer not using the product or its components (1) in manufacturing; (2) to provide a service, information, or data to an unaffiliated third party for payment; (3) for therapeutic, diagnostic or prophylactic purposes; (4) to resell, sell, or otherwise transfer this product or its components to any third party, or for any other commercial purpose. Life Technologies Corporation will not assert a claim against the buyer of the infringement of the above patents based on the manufacture, use or sale of a commercial product developed in research by the buyer in which this product or its components was employed, provided that neither this product nor any of its components was used in the manufacture of such product. For information on purchasing a license to this product for purposes other than research, contact Life Technologies Corporation, Cell Analysis Business Unit, Business Development, 29851 Willow Creek Road, Eugene, OR 97402, Tel: (541) 465-8300. Fax: (541) 335-0354.
Citation for Human CXCL13/BLC/BCA-1 Alexa Fluor® 700-conjugated Antibody
R&D Systems personnel manually curate a database that contains references using R&D Systems products. The data collected includes not only links to publications in PubMed, but also provides information about sample types, species, and experimental conditions.
1 Citation: Showing 1 - 1
Pathologically expanded peripheral T helper cell subset drives B cells in rheumatoid arthritis
Authors: DA Rao, MF Gurish, JL Marshall, K Slowikowsk, CY Fonseka, Y Liu, LT Donlin, LA Henderson, K Wei, F Mizoguchi, NC Teslovich, ME Weinblatt, EM Massarotti, JS Coblyn, SM Helfgott, YC Lee, DJ Todd, VP Bykerk, SM Goodman, AB Pernis, LB Ivashkiv, EW Karlson, PA Nigrovic, A Filer, CD Buckley, JA Lederer, S Raychaudhu, MB Brenner
Sample Types: Whole Cells
Applications: Flow Cytometry
No product specific FAQs exist for this product, however you mayView all Antibody FAQs
Reviews for Human CXCL13/BLC/BCA-1 Alexa Fluor® 700-conjugated Antibody
There are currently no reviews for this product. Be the first to review Human CXCL13/BLC/BCA-1 Alexa Fluor® 700-conjugated Antibody and earn rewards!
Have you used Human CXCL13/BLC/BCA-1 Alexa Fluor® 700-conjugated Antibody?
Submit a review and receive an Amazon gift card.
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image